Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Recruiting

Phase 3

DeuruxolitinibStudy to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Sponsor:

Sun Pharmaceutical Industries, Inc.

Code:

NCT07133308

Conditions

Alopecia Areata

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Deuruxolitinib

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-06. This information was provided to ClinicalTrials.gov by Sun Pharmaceutical Industries, Inc. on 2026-01-28.